PHARMACY

Mylan comments on Perrigo lawsuit

BY DSN STAFF

HERTFORDSHIRE, England, and PITTSBURGH — In the latest on the Mylan bid for Perrigo, Mylan on Thursday released a statement about the Perrigo lawsuit filed in Israel on Thursday.

The statement read:

“Mylan believes that the Perrigo suit filed in Israel [Thursday] is entirely without merit and that Mylan's offer in Israel is valid and proper in all respects.

“With that said, Perrigo's efforts are entirely futile, as all Perrigo shareholders — institutional and retail, including those in Israel — have always been free to switch their holdings at any time from the Tel Aviv Stock Exchange to the New York Stock Exchange, through a simple, fully automated, well-established system by notifying their broker. As a result, shareholders can participate fully in Mylan's compelling offer without regard to any lawsuits in Israel or any other frustrating actions pursued by Perrigo in Israel.

“Further, as Mylan has previously stated publicly, it has been our intent and desire to list Mylan's shares on the TASE to maintain liquidity in Israel for the convenience of those shareholders in Israel who prefer to trade on the TASE, and Mylan is already well-advanced in the process of submitting its application to the TASE and the Israel Securities Authority, and is committed to continuing to work closely with these parties to complete this process.”

Click here for more on the Mylan bid for Perrigo.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Report: Pharmacists to increasingly learn alongside other health professionals

BY DSN STAFF

HAGUE, Netherlands — Learning together with other health professionals might become more mainstream for pharmacists, according to a report published Friday by the International Pharmaceutical Federation Education Initiative.

Interprofessional curriculums could become more common in classrooms and clinical settings, according to the report “Interprofessional education in a pharmacy context: Global report 2015.”

“As the number and complexity of treatments grow, it’s no longer possible for any one health provider — no matter how knowledgeable — to be able provide top quality care working in isolation,” said report co-author Tina Brock.

The report presented examples of multidisciplinary education from around the world, including the development of an interprofessional curriculum at the University of Queensland in Australia, and oncology nurses training in a hospital pharmacy department in Uruguay.

Interprofessional education may be an area of pharmacy where developing countries are active, using new models that others can replicate, according to the report. “In under-resourced countries, there is typically a shortage of health professionals. This provides additional motivation for professionals in emerging systems to combine forces,” Brock said.

“In the United States and many western systems, we’re now spending significant resource in retraining people who were educated separately to work together in high performing teams,” Brock continued. “If under-resourced countries never build those professional ‘silos’, they will not have to expend precious resource to tear them down.”  

Pharmacists and educators will gather next week to discuss interprofessional education at the World Congress of Pharmacy and Pharmaceutical Sciences in Düsseldorf, Germany.

Click here to view the full International Pharmaceutical Federation Education Initiative report.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Teva to acquire Gecko Health Innovations

BY DSN STAFF

JERUSALEM and CAMBRIDGE, Mass. — Teva Pharmaceutical on Friday announced that it entered into a definitive agreement to acquire Gecko Health Innovations, which focuses on developing software and product solutions to aid in compliance and adherence improvement in the management of respiratory diseases.

"The acquisition of Gecko Health Innovations further enhances Teva's ability to develop and deliver truly patient-centered solutions by utilizing e-connected, data-driven technology to improve the management of respiratory diseases," said Rob Koremans, president and CEO of Teva Global Specialty Medicines.

Through the agreement, Teva will acquire CareTRx, a cloud-based solution developed by Gecko Health Innovations to simplify chronic respiratory disease management, connecting patients and caregivers through remote monitoring and real-time adherence tools. CareTRx is comprised of a hardware device that attaches to most metered-dose inhalers, as well as a software program which synchronizes and stores data through an app-based user interface.  

"During the last three years, we have designed and built a system to support respiratory disease management by intuitively connecting caregivers, patients and families," said Dr. Yechiel Engelhard, CEO and founder of Gecko Health Innovations. "In founding Gecko Health Innovations, our vision was to connect chronic medication management into one platform, leveraging this information to support and empower patients by partnering with leading players in the health care and pharmaceutical industries. We are very excited to realize this vision as it aligns to Teva's focus on innovative patient solutions."

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?